company background image
0KCS logo

OPKO Health LSE:0KCS Stock Report

Last Price

US$1.51

Market Cap

US$1.0b

7D

-7.7%

1Y

-8.0%

Updated

25 Dec, 2024

Data

Company Financials +

0KCS Stock Overview

A healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. More details

0KCS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

OPKO Health, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for OPKO Health
Historical stock prices
Current Share PriceUS$1.51
52 Week HighUS$1.75
52 Week LowUS$0.85
Beta1.63
1 Month Change-7.13%
3 Month Change-1.03%
1 Year Change-7.95%
3 Year Change-69.72%
5 Year Change-1.63%
Change since IPO-69.16%

Recent News & Updates

Recent updates

Shareholder Returns

0KCSGB HealthcareGB Market
7D-7.7%-0.05%-0.6%
1Y-8.0%-25.9%3.1%

Return vs Industry: 0KCS exceeded the UK Healthcare industry which returned -25.9% over the past year.

Return vs Market: 0KCS underperformed the UK Market which returned 3.1% over the past year.

Price Volatility

Is 0KCS's price volatile compared to industry and market?
0KCS volatility
0KCS Average Weekly Movement6.2%
Healthcare Industry Average Movement5.0%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0KCS has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0KCS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20073,930Phil Frostwww.opko.com

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.

OPKO Health, Inc. Fundamentals Summary

How do OPKO Health's earnings and revenue compare to its market cap?
0KCS fundamental statistics
Market capUS$1.02b
Earnings (TTM)-US$133.73m
Revenue (TTM)US$711.41m

1.4x

P/S Ratio

-7.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0KCS income statement (TTM)
RevenueUS$711.41m
Cost of RevenueUS$627.03m
Gross ProfitUS$84.38m
Other ExpensesUS$218.11m
Earnings-US$133.73m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.20
Gross Margin11.86%
Net Profit Margin-18.80%
Debt/Equity Ratio31.4%

How did 0KCS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 13:38
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OPKO Health, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Louise ChenCantor Fitzgerald & Co.
Dana FlandersGuggenheim Securities, LLC